Escitalopram Acid
✓
100% accuracy
of data
24/7 scientific
support
⬡
0% tolerance in
quality of product

Stock Locations

  • New Jersey, USA
  • Czech Republic, EU
  • Mumbai, India

* Stock subject to availability.

Documentation

Download MSDS

Download Sample COA

Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.

Escitalopram Acid

● In Stock

Catalogue No.:VE0025655
CAS No.:N/A
Mol. Formula:C20H21FN2O3
Mol. Weight:356.39 g/mol

Additional information on

Parent drug

Escitalopram

IUPAC Name

5-cyano-2-(4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl)benzoic acid

Synonyms

5-cyano-2-(4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl)benzoic acid

Smiles

O=C(O)C1=CC(C#N)=CC=C1C(C2=CC=C(F)C=C2)(CCCN(C)C)O

InChI

InChI=1S/C20H21FN2O3/c1-23(2)11-3-10-20(26,15-5-7-16(21)8-6-15)18-9-4-14(13-22)12-17(18)19(24)25/h4-9,12,26H,3,10-11H2,1-2H3,(H,24,25)

Description

Escitalopram Acid, 5-cyano-2-(4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl)benzoic acid, is a polar acidic degradation impurity observed during synthesis and stability of escitalopram. It can form via oxidative hydrolysis and exhibits increased polarity relative to the parent amine, leading to early HPLC retention and a characteristic [M-H]- ion in LC-MS. Control strategies include validated HPLC-UV and LC-MS assays, forced degradation profiling, and NMR confirmation for structural assignment. Specification limits are set based on ICH impurity thresholds and toxicological assessment. Monitoring this impurity is essential for API quality, process optimization, and regulatory compliance.

Request a Quote

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Products quotation
Name
Url